Immunotherapy has brought promising breakthroughs to several types of cancer. Cervical cancer has a relatively large number of mutations (gene changes), which may make it more sensitive to immunotherapy drugs and may apply immunotherapy to cervical cancer.
A number of clinical trials are in full swing, and the researchers recently summarized a phase II trial of single drug nivolumab (Opdivo) for recurrent cervical cancer. Among the 24 patients: 19 had cervical cancer, 5 had vaginal cancer, and 26% of cervical cancer patients responded to the drug, which is an encouraging result.
Researchers will continue to improve the single-drug program through further trials, but are also pursuing another approach: combination trials. Studies using single-agent immunotherapy with drugs such as pembrolizumab (Keytruda) or nivolumab show that 15% -25% of patients are active, but the remaining patients are inactive, and there is much room for improvement. For this reason, the researchers are more focused on combined trials of cervical cancer.
Ana kan gudanar da gwaji don hada maganin mai suna atezolizumab (Tecentriq) tare da wakilin anti-angiogenic bevacizumab, wanda ke hana kwayoyin cutar kanjamau kafa sabbin jijiyoyin jini da ke bukatar girma. Bevacizumab magani ne mai aiki akan cutar sankarar mahaifa, kuma akwai ƙayyadaddun bayanai waɗanda bevacizumab na iya inganta ingancin rigakafin rigakafi. Sabili da haka, wannan haɗuwa ce mai ban sha'awa ta ciwon sankarar mahaifa, kuma muna ɗokin jiran sakamakon wannan binciken.
In another clinical trial, researchers are studying how two immunotherapy drugs, durvalumab (IMFINZI) and tremelimumab, can be combined with radiation therapy to see if radiation can enhance the immune response.
Researcharin bincike kan cututtukan sankarar mahaifa ya ƙara da babban fata ga masu fama da cutar sankarar mahaifa, kuma muna sa ran ingantaccen maganin.
